<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162639</url>
  </required_header>
  <id_info>
    <org_study_id>HM20015249</org_study_id>
    <nct_id>NCT04162639</nct_id>
  </id_info>
  <brief_title>The Relationship Between Cadaveric Allograft Skin and HLA-Sensitivity in Burn Patients</brief_title>
  <official_title>The Relationship Between Cadaveric Allograft Skin and Human-leukocyte Antigens (HLA)-Sensitivity in Burn Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AlloSource</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to look at how the body's immune system reacts to
      temporary skin grafts from deceased donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some burns will heal best with the use of temporary skin grafts from cadavers before covering
      the burns with grafts of the patient's own skin. This is the usual care for these types of
      burn injuries recommended by burn surgeons. This skin is applied in the operating room and
      removed after several days. During that time, the body's immune system will make antibodies
      to the skin. Normally, these antibodies are harmless. However, extra antibodies can make it
      difficult to find donors for transplants. The results of this study will be used to better
      understand how to treat a subset of burn patients with very severe burns in a way that allows
      them to receive tissue transplants (e.g. face transplants, hand transplants).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in participant's panel reactive antibody (PRA) score at 1 month</measure>
    <time_frame>Baseline to 1 month</time_frame>
    <description>Standard PRA assays will be performed on blood samples drawn from participants giving a percent score representing the number of reactions in the sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in participant's panel reactive antibody (PRA) score at 6 months</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Standard PRA assays will be performed on blood samples drawn from participants giving a percent score representing the number of reactions in the sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in participant's panel reactive antibody (PRA) score at 12 month</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Standard PRA assays will be performed on blood samples drawn from participants giving a percent score representing the number of reactions in the sample.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>One donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive skin allograft from 1 distinct cadavers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two donors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive skin allograft from 2 distinct cadavers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Three donors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive skin allograft from 3 distinct cadavers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be burned patients with wounds that do not require skin allografts, but are instead reconstructed with their own skin (skin autografts) in a single stage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Skin allograft</intervention_name>
    <description>Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.</description>
    <arm_group_label>One donor</arm_group_label>
    <arm_group_label>Three donors</arm_group_label>
    <arm_group_label>Two donors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 years or older

          -  Burns of deep partial thickness or full thickness depth totaling less than or equal to
             10% total body surface area.

          -  Injury requiring staged reconstruction with allograft skin (experimental group)

          -  Injury requiring reconstruction with autograft skin (i.e. no cadaver skin; control
             group)

        Exclusion Criteria:

          -  Burns exceeding 10% total body surface area.

          -  Pre-existing allosensitization at time of injury

          -  Blood or blood product transfusion requirement

          -  Pregnancy at the time of injury or during study period

          -  History of solid organ transplant during study period

          -  History of autoimmune disorder (systemic lupus erythematosus, etc.)

          -  History of mechanical circulatory support (extracorporeal membrane oxygenation,
             ventricular assist device, total artificial heart) during study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Feldman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Goodreau, MD</last_name>
    <phone>8048283033</phone>
    <email>adam.goodreau@vcuhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Feldman, MD</last_name>
    <phone>8048283033</phone>
    <email>michael.feldman@vcuhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Duhamel P, Suberbielle C, Grimbert P, Leclerc T, Jacquelinet C, Audry B, Bargues L, Charron D, Bey E, Lantieri L, Hivelin M. Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation. Transpl Int. 2015 May;28(5):582-93. doi: 10.1111/tri.12540. Epub 2015 Feb 26.</citation>
    <PMID>25683513</PMID>
  </reference>
  <reference>
    <citation>Klein HJ, Lehner F, Schweizer R, RÃ¼si-Elsener B, Nilsson J, Plock JA. Screening of HLA sensitization during acute burn care. Burns. 2018 Aug;44(5):1330-1335. doi: 10.1016/j.burns.2018.01.010. Epub 2018 Mar 7.</citation>
    <PMID>29929900</PMID>
  </reference>
  <reference>
    <citation>Klein HJ, Schanz U, Hivelin M, Waldner M, Koljonen V, Guggenheim M, Giovanoli P, Gorantla VS, Fehr T, Plock JA. Sensitization and desensitization of burn patients as potential candidates for vascularized composite allotransplantation. Burns. 2016 Mar;42(2):246-57. doi: 10.1016/j.burns.2015.05.019. Epub 2015 Sep 29. Review.</citation>
    <PMID>26392022</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

